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Abstract  13 
 14 
Host defense to virus infection involves both resistance mechanisms that reduce viral burden and 15 
tolerance mechanisms that limit detrimental effects of infection. The fruit fly, Drosophila 16 
melanogaster, has emerged as a model to identify and characterize the genetic basis of resistance and 17 
tolerance. This protocol describes how to analyze host responses to virus infection in Drosophila and 18 
covers preparation of virus stocks, experimental inoculation of flies, and assessment of host survival 19 
and virus production, which are indicative of resistance or tolerance. It also provides guidance on how 20 
to account for recently identified confounding factors, including natural genetic variation in the pastrel 21 
locus and contamination of fly stocks with persistent viruses and the symbiotic bacterium Wolbachia. 22 
Our protocol aims to be accessible to newcomers to the field and, although optimized to carry out 23 
virus research using Drosophila, some of the techniques could be adapted to other host organisms 24 
and/or other microbial pathogens. Preparation of fly stocks requires about a month, virus stock 25 
preparation 17-20 days, virus injection and survival assays 10-15 days, and virus titration 14 days. 26 
 27 
 28 
 29 
Keywords 30 
Drosophila, innate immunity, antiviral defense, virus, tolerance, resistance   31 
 3 
INTRODUCTION  32 
 33 
When facing infection, host organisms use at least two combined strategies to fight off microbial 34 
invaders and return to a healthy state. The first strategy, called resistance, involves the activation of 35 
immune pathways that target pathogens to control their replication. The second strategy, termed 36 
tolerance, reduces the impact of infection on host fitness by dampening excessive immune responses 37 
or minimizing tissue damage
1, 2
.  38 
 39 
Here, we describe the use of the fruit fly, Drosophila melanogaster, to uncover mechanisms of 40 
antiviral resistance and tolerance. Drosophila is a well-established genetic model organism that is 41 
widely used to study fundamental aspects of host defense, by virtue of easy stock maintenance, genetic 42 
tractability, and high degree of evolutionary conservation with other metazoans
3, 4
. Studies in 43 
Drosophila uncovered an important role of the RNA interference pathway in resistance to major 44 
classes of viruses
5-9
. In addition, several evolutionarily conserved inducible immune pathways, such as 45 
Toll, Imd, and Jak-Stat, have been shown to contribute in a virus- and tissue-specific manner to 46 
antiviral defense
10-14
. Genetic defects affecting resistance cause high morbidity and mortality due to 47 
incomplete control of virus replication. Conversely, mutants with reduced tolerance present higher 48 
level of pathogenesis, without an increase in viral burden. Resistance and tolerance in Drosophila are 49 
typically assessed by comparing survival between mutant flies and their wild-type controls upon viral 50 
challenge and by analyzing virus loads, for example, by end-point dilution assays or quantitative 51 
reverse transcription-PCR (qRT-PCR). In addition, transcriptional induction of immune genes, such as 52 
those encoding antimicrobial peptides or stress-induced proteins, may be assessed by qRT-PCR or 53 
genome-wide approaches
5, 10-12, 15-17
.  54 
 55 
Several viruses have been used to study antiviral immunity in Drosophila
18
 (Table 1). Amongst them 56 
are natural pathogens that infect wild Drosophila populations (e.g. Drosophila C virus, Nora virus, and 57 
Sigma virus), viruses that were originally identified in other insects, such as crickets (Cricket paralysis 58 
virus), beetles (Flock House virus), or moths (Invertebrate iridescent virus-6)
18
, as well as arthropod-59 
borne viruses that shuttle between blood-feeding insects and vertebrate hosts during their natural 60 
transmission cycle (Vesicular stomatitis virus, Sindbis virus). Viral tropism remains mostly 61 
uncharacterized, but has been reported for some viruses: Drosophila C virus replicates in diverse 62 
tissues, including the fat body, the periovarian sheath, and the digestive tract
15, 19, 20
, Flock house virus 63 
has been characterized as cardiotropic
21
, and Nora virus is an enteric virus that is transmitted through 64 
feces
22
. Pathological symptoms, possibly linked with tissue and cell tropism, have been described for 65 
some viral infections, and these physiological changes may be used as additional read-outs for 66 
infection. For instance, DCV infection of the crop, a nutrient storage organ located at the proximal 67 
region of the digestive track of Drosophila, leads to severe intestinal obstruction
19
. FHV induces 68 
 4 
morphological changes in mitochondria of cardiomyocytes and longitudinal fibers of the cardiac 69 
muscle. Finally, it has been suggested that Sigma virus infects the thoracic ganglion, which might 70 
explain the CO2 sensitivity of infected fly stocks
23
. When selecting a virus for study, it is important to 71 
consider the genetic make-up and replication strategy, natural host, tropism, and systemic effects, as 72 
these parameters may affect the defense response that is induced. 73 
 74 
Recent studies have uncovered several confounding factors that have the potential to dramatically 75 
affect the outcome of experimental infections and skew their interpretation. First, Drosophila 76 
laboratory strains are often persistently infected with RNA viruses, such as Drosophila C Virus 77 
(DCV), Drosophila A virus (DAV), and Nora virus
24-26
. These viruses are inducers and suppressors of 78 
host RNAi pathways, and activate a number of other cellular pathways involved in host physiology 79 
and metabolism
14, 19, 21
. These persistent infections are likely to affect the response to experimental 80 
inoculation with a particular virus, and it is therefore recommended to clear fly stocks of persistent 81 
infections by treating eggs with household bleach. Second, it was demonstrated that infection with the 82 
endosymbiotic bacterium Wolbachia strongly affects resistance to RNA viruses (DCV, FHV, and 83 
Nora Virus), as Wolbachia-infected flies show lower mortality rates and, in the case of DCV, harbor 84 
significantly lower levels of virus. Of note, fly stocks may be infected with different Wolbachia 85 
variants that provide differential protection to virus infection
27,16
. The presence and levels of 86 
endogenous viruses and Wolbachia differ between Drosophila stocks, which makes it difficult to 87 
interpret survival assays obtained from fly lines that differ in their infection status. Therefore, it is 88 
essential to rid fly stocks of viruses and symbionts, prior to experiments investigating resistance and 89 
tolerance
27
. Third, susceptibility of flies to infection can also originate from unaccounted genetic 90 
variability between Drosophila stocks. For example, it has been reported that single nucleotide 91 
polymorphisms (SNPs) in the pastrel locus modulate the susceptibility of flies to DCV infection, but 92 
not to Flock House virus (FHV) or Sigma virus
28
. Another polymorphism, located in the Ref(2)p locus, 93 
confers resistance to Sigma virus
29, 30
. Taken together, it is critical for the correct interpretation of 94 
experimental infections that these confounders are accounted for. 95 
 96 
Overview of the procedure 97 
This protocol describes a series of methods routinely used in our laboratory to study the genetic and 98 
functional basis of tolerance and resistance in the fly
5, 12, 31
. The workflow is depicted in Figure 1. The 99 
key stages are as follows: 100 
1. Preparation of fly stocks (Steps 1-23). This stage is the most time-consuming of the entire 101 
workflow (Fig. 1) and it is recommended to start this procedure as soon as the laboratory 102 
receives a new fly strain. Because of possible infestation of fly stocks with mites, the 103 
incoming stocks should be kept in quarantine
32
. As soon as a critical number of flies has 104 
emerged (≈ 30-50 flies), eggs can be subjected to treatment with bleach. This procedure will 105 
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eliminate extracellular parasites, as well as horizontally transmitted viruses or bacteria that are 106 
present on the outer shell of the egg (chorion), which itself will be dissolved by the treatment. 107 
Dechorionated eggs are then collected and transferred to a vial containing standard fly food. 108 
After 10 days, offspring flies will emerge and successful decontamination is confirmed by 109 
PCR-based assays, using primers for a panel of viruses commonly found in fly stocks (Table 110 
2).  111 
To clear fly stocks of the endosymbiont Wolbachia, flies are treated for 2 generations with the 112 
antibiotic tetracycline, as previously described
16
. Flies are confirmed to be Wolbachia-free 113 
using standard PCR assays on fly DNA extracts, using Wolbachia-specific primers (Table 2).  114 
The final stage in fly stock preparation consists of PCR amplification and sequencing of the 115 
genomic pastrel locus. Six SNPs in pastrel are associated with natural resistance to DCV and 116 
CrPV infection, with a SNP located in the last exon having the strongest effect on DCV 117 
infection
28, 33
 (Figure 3). If discordance in the SNP profile is detected between fly lines to be 118 
analyzed, it will be difficult to determine whether phenotypic differences are due to the allele 119 
of interest, or to variation in the pastrel locus.  120 
 121 
2. Preparation and titration of virus stocks (Steps 24-31). The viral isolate is first amplified 122 
by propagation on Drosophila S2 cells or other cell lines that support replication. Our protocol 123 
has been optimized for DCV, but it can be adapted to other viruses (Table 1 and Experimental 124 
Design). After inoculation, cells should be carefully monitored for cell death (also called 125 
cytopathic effect, CPE) and the culture supernatant is harvested when the viral titers are as 126 
high as possible, but before excessive cell debris appears in the supernatant. The virus stock is 127 
titered using a classic end-point dilution assay, and a 50% Tissue Culture Infectious Dose 128 
(TCID50) is established
40
. S2 cells do not strongly adhere to the culture plate and exhibit poor 129 
viability under agar overlay, which precludes the use of plaque assays for virus titration.  130 
 131 
3. Inoculation of flies (Steps 32-35). We describe inoculation of flies by capillary-mediated 132 
injection. Injection ensures precise control of the viral inoculum and triggers an immediate 133 
systemic infection. Alternative methods, which are described in detail elsewhere
13, 27, 34-37
, are 134 
discussed in Experimental Design. 135 
 136 
4. Assessment of survival and viral load (Steps 36-42). Survival of infected flies is measured 137 
daily by scoring the number of dead flies in each test tube. Survival data can be evaluated 138 
using Kaplan-Meier and Cox proportional hazard analyses, which allow inclusion of censored 139 
cases, such as flies that are lost to follow-up and flies that have not died at the end of follow-140 
up
49
. Viral loads may be assessed by end-point dilution assays using the Reed and Muench 141 
method
40
. Time courses may be needed, as differences in viral titers might be detectable only 142 
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at some stages of the infection. In end-point dilution assays, cell death is monitored visually 143 
over time and scored after 14 days. Note that DCV only induces mild CPE, which necessitates 144 
this long follow-up during titration. Viruses that induce stronger CPE, such as Cricket 145 
paralysis virus (CrPV), can be scored at an earlier time-point. 146 
 147 
Advantages and limitations of the protocol 148 
Our protocol describes virus inoculation by injection, rather than more natural routes, such as feeding. 149 
Injection warrants high experimental reproducibility and systemic infection of all flies within an 150 
experiment. However, reliable protocols for natural infections have been developed recently, and are 151 
discussed below (Experimental design, virus inoculation). One putative limitation of our protocol for 152 
fly stock preparation is that it is impossible to eliminate viruses that infect germline cells, such as 153 
Sigma virus, by bleaching. It had been suggested that transmission of Sigma virus was strongly 154 
reduced, or even absent, in aged flies
23, 38
. However, Sigma virus only infects about 4% of Drosophila 155 
in the wild
39
, and does not seem to be present in laboratory stocks, therefore vertically transmitted 156 
viruses do not represent a major concern when using standard fly stocks.  157 
 158 
Experimental design 159 
Genetic background. If flies are discordant in the pastrel locus, it is recommended to isogenize the 160 
genetic background of the fly line of interest by genetic crosses or by sequential back-crosses to the 161 
control strain, using methods previously described
27, 40
. It has recently been reported that natural 162 
genetic variation in other loci (Ubc-E2H and CG8492) is also associated with DCV sensitivity, and 163 
with susceptibility to other viruses (Ubc-E2H, CrPV; CG8492, FHV), even though the presence of 164 
such genetic variation in laboratory stocks remains to be formally demonstrated
33
. It is possible that 165 
additional as-yet-unknown polymorphic loci may affect the sensitivity to DCV and other viruses. 166 
Although labor-intensive, isogenizing the strain of interest to the control strain will effectively 167 
eliminate the contribution of unknown polymorphic sites to the observed resistance and tolerance 168 
phenotypes. Alternatively, a direct link between a gene and a resistance phenotype can be confirmed 169 
using additional alleles of the gene of interest, which could include RNAi-knockdown lines, by 170 
analyzing a deficiency line that uncovers the locus of the gene of interest, or by performing genetic 171 
rescue experiments.  172 
Preparation of virus stock. Several viruses are currently used in Drosophila laboratories to analyze 173 
resistance and tolerance to infection. A list of the most commonly used viruses is provided in Table 1. 174 
If no susceptible cell line is available for virus amplification, or when cell culture does not support a 175 
high level of replication (for example Nora virus and Drosophila A virus), a virus stock may be 176 
amplified in infected adult flies and purified on a sucrose density gradient
16, 41, 42
. It is important to be 177 
aware that some Drosophila S2 cell lines, such as S2R+, may be chronically infected with multiple 178 
viruses, including the Flock house virus (FHV) variant American nodavirus (ANV) 
43, 44
. Virus stocks 179 
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should therefore be prepared on cell lines that are not persistently virus infected, which can be 180 
assessed by RT-PCR, as described previously
43-45
. After inoculation, the optimal time of harvesting 181 
may depend on the virus used, its CPE-inducing effects, and on the titer of the inoculum, and should 182 
therefore be experimentally established. In the Procedure, we describe preparation of viral stocks by 183 
centrifugation, but they can also be purified and concentrated using sucrose-gradient centrifugation, as 184 
previously described
46
.  185 
Virus inoculation. We describe methods for systemic infection of flies by capillary-mediated 186 
injection. However, flies can also be infected by pricking with tungsten needles or with 0.15 mm 187 
diameter insect pins
27, 37
, by feeding on experimentally contaminated fly food, or by exposure to virus-188 
containing sucrose solution
35, 36
. We use injection because it allows precise control of inoculation and 189 
triggers an immediate systemic infection. Also, injection is often better for delivery of a lethal dose, 190 
whereas infection by feeding generally triggers a slower, milder, and sometimes local infection, as 191 
illustrated by low mortality rates in orally infected fly stocks
13, 34
. Moreover, the route of inoculation 192 
may influence the sequence in which target tissues are infected, and thereby, the nature and magnitude 193 
of the immune response. With this in mind, the site of injection should be consistent, as it may define 194 
the initial site of replication and could theoretically influence the experimental outcome. Limited 195 
experimental data are available on this issue for virus infections, but the injury site has been shown to 196 
influence the outcome of bacterial infection in Drosophila
47, 48
. We tested whether the injection site 197 
changed the outcome of systemic DCV infection, but no difference in survival rates was noted 198 
between intra-thoracic and intra-abdominal injections (Fig. 4a, P = 0.104, log-rank test, see 199 
supplementary data 1 for further statistics). However, we cannot exclude that the injection site could 200 
affect the course of other virus infections. 201 
Gender and age of flies. Either male or female flies can be used for survival experiments, but female 202 
flies may be easier to inject due to their larger size. Moreover, as males do not deposit eggs and no 203 
larvae grow in the medium, it easily dries out and requires more frequent passages to fresh vials. A 204 
small difference in survival can occur between genders (Fig. 4b, P < 0.001, supplementary data 1) and 205 
this must be taken into account by analyzing one sex only within a single experiment. Flies should be 206 
staged, e.g. at three-to-five days old, as aging influences survival rates
40, 49
. This can be further 207 
optimized and standardized for a given virus or study.  208 
Controls. It is critical to include all necessary controls in survival assays. The genetic background 209 
may affect the experimental outcome, as illustrated here by comparing survival of 3 different control 210 
strains (w
1118
, Cinnabar Brown, Oregon-R) upon DCV infection (Fig. 4c, P < 0.001 for OreR, and P = 211 
0.085 for CnBw, compared to w
1118
, supplementary data 1). For genetic mutants, a strain with the best-212 
matched genetic background should therefore be used as a control. When analyzing the offspring of 213 
genetic crosses, for example between a Gal4-driver line with a UAS-responder line, it is recommended 214 
to include the offspring of control crosses of the driver line and the responder line to the corresponding 215 
wild-type strain. In addition, mock infections must be performed alongside the experimental 216 
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infections. Mutant lines might be sensitive to the stress caused by the needle injury, the incubation 217 
temperature, or natural aging, and putative differences in survival between fly lines might not be fully 218 
attributed to the viral infection. Additionally, when investigating the activation of immune pathways, 219 
normalization to a mock control is essential, as the injury itself induces a small, but non-negligible 220 
immune response
50
.  221 
Determining the optimal inoculum. Pilot studies should be performed to monitor survival upon 222 
inoculation of 10-fold serial dilutions of viral stocks, as shown for different DCV doses in wild-type 223 
flies (Fig. 4d, supplementary data 1). The virus dose should not be too high to mask possible 224 
differences between genotypes, but high enough to ensure that all flies are consistently infected. We 225 
typically use 1,000 TCID50 units, but depending on the aim of the experiment a range of doses from 226 
100 to 10,000 TCID50 units may be used.  227 
Growth conditions. After virus inoculation, flies are kept in an incubator with controlled l2h-228 
light/dark cycles and constant temperature (typically 25°C), and transferred to fresh food every 3 days 229 
to avoid excessive sogginess caused by larval growth, which would cause adult flies to stick to the 230 
food and drown during oviposition and feeding. Temperature strongly influences the time-course of 231 
the survival: higher temperature (29°C) accelerates death and subjects flies to mild heat stress, 232 
whereas lower temperature slows down virus-induced mortality (Fig. 4e).  233 
Survival assays. Survival tests may be performed using replicate tubes within a single experiment, for 234 
example using three replicates with a minimum of 15 flies per replicate. This will give an indication of 235 
intra-experimental variability and prevents that unaccounted technical factors, such as food quality, 236 
affect the outcome of the assay. Survival assays should be repeated 3 times to evaluate inter-237 
experimental reproducibility. Survival data can be evaluated using Kaplan-Meier and Cox 238 
proportional hazard analyses. In Kaplan-Meier analyses, the log-rank test can be used to assess 239 
whether differences in survival are statistically significant, but it will not assess effect size. Difference 240 
in mean survival and associated 95% confidence intervals or standard errors may be reported as a 241 
quantitative measure of the effect of a genetic allele on survival. Cox proportional Hazard analyses 242 
(also known as Cox regression) estimate a hazard ratio (and associated 95% confidence interval) for 243 
the condition of interest relative to a reference condition, which can be reported as a measure of effect 244 
size. Other covariates, such as replicates within an experiment, repeats of the experiment, or sex, can 245 
be analyzed along with the parameter of interest and the reported hazard ratios then account for 246 
variation in covariates. Kaplan-Meier and Cox proportional hazard analyses of the survival 247 
experiments in Figure 4 are provided in Supplementary table 1.  248 
Viral load assessment. Multiple independent samples are analyzed to account for experimental 249 
variation (for example, 3 biological replicates of 5 flies minimum; numbers can be adjusted according 250 
to the aim of the experiment). It is recommended to prepare a mock sample, to ensure that no other 251 
component in the fly lysate induces cell death that could be misinterpreted as virus-induced CPE. The 252 
end-point dilution assay requires viruses to replicate and cause CPE in cell culture. If those 253 
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requirements are not met, additional techniques to quantify virus production are available: qRT-PCR 254 
assays, which quantifies viral RNA with greater sensitivity, but does not assess infectious virus, qPCR 255 
to quantify genome copies of DNA viruses, and western blot analyses to detect viral proteins 
5, 11, 12, 15, 256 
51
. Of note, the sensitivity limits of virus titration or western blots may not allow to readily or 257 
consistently detect small differences in viral titers (< 0.5 log). While differences in viral titers might 258 
appear mild in the whole organism, experiments using organ or tissue dissection (e.g. gut, or fat body) 259 
might unveil tissue-specific differences in viral load
12, 15
. Organ dissection, and microscopy-based 260 
approaches may also be used as to evaluate tropism, and to determine sites with high level of 261 
infection
13, 15, 19, 21
.   262 
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MATERIALS   263 
 264 
REAGENTS 265 
 Drosophila stocks (w1118, Cinnabar Brown, and Oregon-R available from Bloomington 266 
Drosophila Stock Center, stock number: #3065, #264, #5, respectively)  267 
 Drosophila viruses, available upon request from academic laboratories  268 
 Drosophila S2 cells (Life technologies, cat. no. R690-07) 269 
 Schneider's Drosophila medium (Life technologies, cat. no. 21720) 270 
 Penicillin (5,000 U/mL)-Streptomycin (5000 µg/mL) (Life technologies, cat. no. 15070) 271 
 Fetal Bovine Serum (FBS), qualified, heat inactivated (Life technologies, cat. no. 10500-064) 272 
 TaqMan reverse transcription reagents (Life technologies, cat. no. N8080234)  273 
 Standard PCR reagents: OneTaq DNA polymerase (New England Biolabs, cat. no M0480), 274 
dNTPs (New England Biolabs, cat. no N0447L), or equivalent reagents   275 
 Phusion High-Fidelity DNA Polymerase (New England Biolabs, cat. no. M0530) 276 
 Custom oligonucleotides (described in Table 2) (Sigma-Aldrich)  277 
 DNA isolation kit (QIAamp DNA Blood Mini Kit) (Qiagen, cat. no. 51104) 278 
 Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, cat. No. 28-9034-70), 279 
or equivalent kit  280 
 Multipurpose agarose (Roche, 11388991001) 281 
 Common fly food reagents: cornmeal and sucrose (Genesee Scientific cat. no. 62-100 and 62-282 
112, or general store) 283 
 Select Agar, powder (Life Technologies, cat. no. 30391) 284 
 Isol-RNA lysis reagent (5 Prime, cat. no. 2302700)  285 
CAUTION: Toxic upon skin contact of inhalation. Handle only under a chemical hood and 286 
wear protective equipment.  287 
 Good quality apple or grape juice (General store)  288 
 Baker’s yeast (Fermipan Red Dried Yeast, or any equivalent product) 289 
 Methylparaben (Sigma-Aldrich, cat. no. 47889). Prepare 3% (w/v) methylparaben solution in 290 
80% ethanol.  291 
CAUTION: Irritant upon contact, inhalation, or ingestion. Wear protective equipment.  292 
 Proprionic acid (Sigma-Aldrich, cat. no. 402907) 293 
CAUTION: Flammable. Irritant upon contact, inhalation, or ingestion. Handle only under a 294 
chemical hood and wear protective equipment.  295 
 Tetracycline (Sigma-Aldrich, Cat. no. 87128). Prepare tetracycline stock solution at 5 mg/mL 296 
in 80% ethanol. 297 
CAUTION: Irritant. Wear protective equipment.  298 
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 80% RNase free ethanol 299 
 Isopropanol 300 
 Sterile PBS 1x 301 
 10 mM Tris-HCl, pH 7.3 302 
 10 mM Tris-HCl, pH 8.2  303 
 1 mM EDTA, pH 8.0 304 
 25 mM NaCl 305 
 Proteinase K (20 mg/ml) (Ambion, Life technologies, cat. no. AM2564) 306 
 TAE buffer 1x 307 
 80% (v/v) ethanol / 10% household bleach (v/v) solution  308 
 50% household bleach (v/v) solution  309 
 Chloroform  310 
CAUTION: Irritant upon contact, inhalation, or ingestion. Handle only under a chemical hood 311 
and wear protective equipment.  312 
 Autoclaved milli-Q ultrapure water 313 
 Demineralized water  314 
 315 
EQUIPMENT 316 
 96-well sterile cell culture plates with flat bottom (Sigma-Aldrich, cat.no. CLS3596) 317 
 96-well sterile cell culture plates with round bottom (Sigma-Aldrich, cat.no CLS3799) 318 
 Cell culture flasks (T25; Sigma-Aldrich, cat.no CLS3055 and T75; Sigma-Aldrich, cat.no 319 
CLS430725 ) 320 
 Sterile 5 mL, 10 mL, 25 mL serological pipettes (Sigma-Aldrich, cat. no. CLS4051, CLS4101, 321 
CLS4251) 322 
 Whatman Puradisc 30 syringe filters, cellulose acetate, 0.2 μm (Sigma-Aldrich, cat. no. 323 
WHA10462200) 324 
 BD Plastipak 50 mL sterile syringe (BD Medical Sciences, cat. no. 300866) 325 
 Large embryo collection cages (Genesee Scientific, cat. no. 59-101) and large replacement 326 
End caps (Genesee Scientific, cat. no. 59-103) 327 
 Sterilin Standard 90mm Petri Dishes (Thermo Scientific, cat. no. 101VR20) 328 
 Narrow Fly Vials (Genesee Scientific, cat. no. 32-109) 329 
 Cotton plugs (Genesee Scientific, cat. no. 51-101) 330 
 Mesh nitex (filter for embryo collection), pore size 120 µm, open area 49% (Genesee 331 
Scientific, cat. no. 57-102)  332 
 Filter paper (Whatman cellulose chromatography paper, Sigma-Aldrich, cat. no. 333 
WHA3030917) 334 
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 Cordless hand-operated motor (Sigma-Aldrich, cat. no. Z359971), to be used in combination 335 
with pellet pestles, blue polypropylene, autoclavable (Sigma-Aldrich, cat. no. Z359947) 336 
 1.5 mL Eppendorf tubes (Eppendorf, cat. no. 0030125150) and 50 mL centrifuge tubes 337 
(Corning, cat. no. 430829) 338 
 Pasteur capillary pipette, length 230 mm (Hecht assistant, cat. no. 567/2)  339 
 Flaming/Brown type micropipette puller (Sutter, cat. no. P-97) 340 
 Injector (Nanoject II, Drummond Scientific company, cat. no. 3-000-204) with foot switch 341 
(cat. no. 3-000-026) 342 
 Glass capillaries (3.5’’, Drummond Scientific Company, cat. no. 3-000-203-G/X) 343 
 Paintbrush (size 0 or 1) 344 
 Stereomicroscope (Zeiss, SteREO Discovery.V8) 345 
 Fly pad on CO2 supply (Genesee Scientific, cat. no. 59-114)  346 
 Bunsen burner 347 
 Fly incubator with l2h-light/dark cycle and adjustable temperature  348 
 Cell culture incubator with adjustable temperature  349 
 Laminar flow tissue culture hood 350 
 351 
REAGENT SETUP 352 
 Handling new fly stocks 353 
After receipt of new fly stocks, place them in quarantine outside the fly room. Wait until a 354 
critical amount of flies (about 30-50) is obtained. Monitor and, if needed, eliminate mites as 355 
previously described
32
. Once confirmed to be mite-free, fly stocks can be transferred to the fly 356 
room and maintained using standard methods.  357 
 358 
 Yeast paste  359 
Mix 10 grams of dry baker’s yeast with 15-20 mL of demineralized water. Stir until the yeast 360 
is dissolved and add water until the paste has the consistency of peanut butter. Yeast paste can 361 
be stored for 3 days at 4°C. 362 
 363 
 Apple Juice-Agar medium (for 20 plates) 364 
Mix 6 grams of agar with 100 mL demineralized water. Boil until the agar is dissolved. Add 365 
100 mL of apple juice. Boil again. While the mix cools down, dissolve 0.2 grams of 366 
methylparaben in 1 mL of 80% ethanol and add to the apple juice agar. Pour 10 mL of the 367 
medium in a Petri dish and let it dry for 1 hour.  For use as egg-laying plates, deposit 1-2 368 
grams of yeast paste on the center of the apple juice-agar plate. Before addition of yeast paste, 369 
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plates can be stored at +4°C for up to 3 weeks. Once yeast paste has been added, plates can be 370 
stored at +4°C for 2 days.  371 
CAUTION: Content easily boils over and needs to be monitored carefully. 372 
CRITICAL: To avoid evaporation and degradation by heat, add the methylparaben only when 373 
the medium is lukewarm (50°C).  374 
 375 
 Fly food (for 30 tubes) 376 
Fly food should be made at least one day before use. Weigh dry ingredients: 2 grams agar, 8 377 
grams dry baker’s yeast, 16 grams cornmeal, 33 grams sucrose. Blend and add, while stirring, 378 
to 300 mL of boiling demineralized water. Slowly cook the mixture for 5 min, and let cool 379 
down. When lukewarm (50°C), add 1 mL methylparaben stock solution and 0.75 mL 380 
propionic acid. For use in tetracycline treatment (step 13), fly food can be supplemented with 381 
3 mL tetracycline stock solution at this point. Pour 10 mL of medium in each small fly vial, 382 
cover the vials with clean tissue or cheesecloth and let dry at room temperature (20°C) for a 383 
day. Fly food can be stored at +4°C for up to 3 weeks.  384 
CRITICAL: To avoid evaporation and degradation by heat, add methylparaben, tetracycline 385 
and propionic acid only when the medium is lukewarm (50°C).  386 
CAUTION: Propionic acid is flammable and can cause skin corrosion. Wear protective 387 
equipment, and handle with care under a chemical hood. Once diluted in the fly food, it can be 388 
handled outside the hood.  389 
 Squishing buffer 390 
10mM Tris-HCl pH 8.2, 1mM EDTA, 25mM NaCl and 200 μg/mL proteinase K added 391 
freshly 392 
 Supplemented Schneider’s Drosophila medium  393 
Supplement Schneider’s Drosophila medium with 10% heat-inactivated FBS and Penicillin 394 
(50 U/mL)-Streptomycin (50 µg/mL). Filter the FBS through a 0.2 μm filter using a sterile 395 
syringe. The medium can be stored at +4°C for 2 months.  396 
 397 
EQUIPMENT SETUP 398 
 Injection needles  399 
Pull the capillaries to prepare injection needles using the Flaming/Brown type micropipette puller 400 
with the following settings: Temperature: 680, Pull: 50, Velocity: 50, Time: 200. Capillary 401 
needles may also be prepared on other models.  CRITICAL: These settings are given as an 402 
example, they may need further optimization.   403 
 Oil-filling injection needles 404 
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Prepare a Pasteur pipette for back-filling the injection needle by melting the Pasteur capillary 405 
using the flame of a Bunsen burner, and gently pull it apart to obtain a very thin end. Back-fill the 406 
injection needle with a non-compressible fluid (e.g. mineral oil) using the Pasteur pipette 407 
mounted with a bulb. Attach a bulb to the pipette and fill it with mineral oil. Insert the pipette into 408 
the capillary needle until it reaches the tip. Gently release the oil while slowly withdrawing the 409 
Pasteur pipette. Make sure not to form any bubbles in the capillary. Oil-filled injection needles 410 
can be stored for several months at room temperature in a petri dish. 411 
 412 
PROCEDURE 413 
 414 
Fly preparation: Egg bleaching TIMING 1 day 415 
1. Transfer flies to egg-laying cages using CO2 anesthesia, place an apple juice plate 416 
(with yeast paste, see Reagent Setup) on top, and seal using the end cap. After the 417 
flies have recovered from anesthesia, place the cage in an incubator at 25°C for a 418 
minimum of 6-8 hours to overnight.   419 
2. Collect eggs into a filter placed in demineralized water; the filter can be built using 420 
fine nylon mesh and a 50 mL Falcon tube (Fig. 2). Retrieve eggs from the apple juice-421 
agar medium using a clean paintbrush. If only a few eggs (less than 20) are present on 422 
the apple juice-agar plate, place the dish under the stereoscope and pick eggs one-by-423 
one with the brush and transfer them to the filter. If many eggs have been deposited 424 
on the agar, remove the yeast paste from the dish, add 3mL of demineralized water, 425 
and gently brush the surface to loosen the eggs without detaching the agar media. 426 
Pour the liquid into the filter. 427 
CRITICAL STEP: It is imperative that the brush is clean and does not contain eggs 428 
from previous collections to prevent genotypic mix-up and contamination (verify 429 
under a stereomicroscope). This is particularly important when collecting different 430 
genotypes in parallel.  431 
3. Transfer the filter containing the eggs in a 50% household bleach and incubate at 432 
room temperature for exactly 10 min. This step dechorionates the eggs.  433 
CRITICAL STEP: Carefully time the treatment to 10 min. The treatment should be 434 
long enough for the chorion to dissolve, but excessive treatment will compromise 435 
embryo viability. Timing may need adjustment depending on the brand of household 436 
bleach. Successful dechorionation will remove the respiratory appendages of the egg, 437 
which can be visualized with the stereomicroscope. 438 
4. Transfer the filter to water and perform three 5-min washes. Dechorionated eggs tend 439 
to aggregate and float on the water surface.  440 
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5. Collect the eggs by gently withdrawing them from the water using a strip of filter 441 
paper of 1x5cm; fold the paper on one end and scoop out the eggs.  442 
CRITICAL STEP Do not use a pipette, as dechorionated eggs will stick to the pipette 443 
tip.  444 
6. Transfer the filter paper to a vial containing standard cornmeal-agar medium, and 445 
incubate at 25°C until adults emerge, about 10 days later.  446 
CRITICAL STEP: Ensure that the filter paper stays wet while the eggs develop by 447 
adding drops of water on it when needed.  448 
CRITICAL STEP: If substantial amounts of eggs (>100) have been collected, it is 449 
possible to shorten the protocol by transferring eggs directly to tetracycline-containing 450 
medium (step 13). RT-PCR and PCR screens for RNA viruses (Step 7) and 451 
Wolbachia (step 16) can then be performed after tetracyline treatment. Note that 452 
larvae seem to develop less well on tetracycline-containing medium; this shorter 453 
protocol is therefore not recommended for weaker stocks or when few eggs have been 454 
collected.   455 
 456 
Fly preparation: confirming absence of RNA viruses by RT-PCR TIMING 1 day 457 
7. Freeze 5 newly emerged adult flies at -20°C, and extract RNA using Isol-RNA lysis 458 
reagent using the manufacturer’s instructions. Include a positive control, such as a 459 
non-bleached fly stock that is known to be persistently virus-infected.  460 
8. Perform a reverse transcription (RT) reaction on 1 μg of RNA using TaqMan Reverse 461 
Transcription Reagents or equivalent reagents. Assemble the following reagents for 462 
each reaction: 463 
 464 
Component Amount (μL) Final Concentration 
10x RT Buffer 2 1x 
25 mM MgCl2 4.4 5.5 mM 
10mM dNTP Mix (2.5 
mM each) 
4 2 mM (0.5 mM each) 
50 μM random hexamers 1 2.5 μM 
RNase inhibitor (20 U/μL) 0.4 0.4 U/μL 
Multiscribe RT (50 U/μL) 0.5 1.25 U/μL 
Template  1 μg RNA, diluted in 7.7 
μL RNase-free water 
 
Total 20 μL (for 1 reaction)  
 465 
 466 
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9. Perform the RT reaction using the following conditions:  467 
 468 
Cycle 
number 
Anneal Extend Inactivate RT enzyme 
1 25°C, 10 min   
2  48°C, 1h  
3   95°C, 5 min 
 469 
CRITICAL STEP: It is recommended to use random hexamers instead of poly-dT 470 
primers during complementary DNA (cDNA) synthesis, since not all viruses produce 471 
poly(A) tailed RNAs.  472 
10. Perform a standard PCR on the cDNA using oligonucleotides targeting DCV, DAV, 473 
Nora virus and other viruses of interest, as well as the housekeeping gene Actin42A 474 
(See oligonucleotide sequences in Table 2). Include a PCR reaction without template 475 
as a negative control. cDNA from non-bleached, virus-infected flies, or plasmid DNA 476 
containing viral sequences can be used as positive controls for PCR. Use the 477 
following set-up when using OneTaq polymerase; adapt when using other PCR 478 
reagents. 479 
 480 
Component Amount (μL) Final Concentration 
5x Reaction Buffer 10 1x 
10mM dNTP Mix (2.5 mM 
each) 
1  200 μM (50 μM each) 
10 μM forward primer 1 0.2 μM 
10 μM reverse primer 1  0.2 μM 
Taq DNA Polymerase (5 
U/μl) 
0.25  
Template (cDNA) 3  
Nuclease-free water 33.75  
Total 50 μL (for 1 
reaction)  
 
 481 
11. Perform PCR using the following cycling conditions:  482 
 483 
Cycle 
number 
Denature Anneal Extend 
1 94°C, 30 sec    
 17 
2-36 94°C, 30 sec 57°C, 30 sec 72°C, 50sec 
37   72°C, 10 min  
 484 
 485 
12. Run 10 μL of each PCR product on a 1% agarose gel in TAE buffer (1x) and verify 486 
the absence of an amplification product for viral sequences. The Actin PCR should be 487 
positive for all samples. See Table 2 for expected sizes of the PCR products.  488 
 489 
Fly preparation: Tetracycline Treatment TIMING ≈25 days  490 
13. Transfer the flies collected after bleaching (at Step 6) to standard cornmeal-agar fly 491 
food supplemented with tetracycline (see Reagent Setup) and let them lay eggs for 3 492 
days. Remove the parents, and, optionally, keep them in a separate tube as back-up. 493 
Return the egg-containing vials to an incubator set at 25°C. 494 
14. When adult F1 progeny eclose, transfer them to a fresh vial with tetracyline-495 
containing food, and repeat the process outlined in step 13.  496 
15. When adult F2 progeny eclose, transfer them to conventional food. Withdraw 5 flies 497 
and transfer them to a 1.5 mL eppendorf tube and freeze at -20°C for confirmation of 498 
Wolbachia-free status by PCR assay (steps 16-18). Return the vials containing the 499 
adults to an incubator set at 25°C, and expand stocks for use in later experiments.  500 
?TROUBLESHOOTING 501 
 502 
Fly preparation: confirming absence of Wolbachia by PCR TIMING 4 hours 503 
16. Make crude DNA extract from the frozen flies from step 15 by adding 50 μL of 504 
squishing buffer (see Reagent Setup) and crushing flies using a pipet tip. Incubate the 505 
mixture at 37°C for 30 min and then inactivate Proteinase K at 95°C for 2 min.  506 
17. Use 3 μL of extract in a 50 μL standard PCR reaction to detect Wolbachia using the 507 
oligonucleotide primers listed in Table 2; use the reaction setup tabulated at step 10 508 
and the cycling conditions tabulated at step 11. Include a negative control (no 509 
template), as well as an extract from Wolbachia-infected flies as a positive control.  510 
18. Run 10 μL of each PCR product on a 1% agarose gel in TAE buffer (1x) and verify 511 
the absence of a Wolbachia amplicon (expected size 610 bp).  512 
?TROUBLESHOOTING 513 
 514 
Fly preparation: Sequencing of the pastrel locus TIMING 1 day 515 
 516 
19. Extract DNA from ≈10 flies from step 15 using the QiAamp DNA Blood Mini 517 
extraction kit. Use between 50-100 ng of DNA as template in a PCR reaction with 518 
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Phusion high-fidelity DNA polymerase or another high-fidelity DNA polymerase to 519 
amplify the pastrel locus. Include a PCR reaction for the housekeeping gene Actin42A 520 
to verify successful DNA isolation, and a PCR reaction without template as a negative 521 
control. Assemble the following reagents for each reaction: 522 
 523 
Component Amount (μL) Final Concentration 
5x Reaction Buffer 10 1x 
10mM dNTP Mix (2.5 
mM each) 
1  200 μM (50 μM 
each) 
10 μM forward primer 2.5 0.5 μM 
10 μM reverse primer 2.5 0.5 μM 
Phusion DNA Polymerase 
(2 U/μl) 
0.5  
Template (50-100 ng) variable   
Nuclease-free water Up to 50 μL  
Total 50 μL (for 1 
reaction)  
 
 524 
20. Perform PCR using the following cycling conditions: 525 
 526 
Cycle 
number 
Denature Anneal Extend 
1 98°C, 1 min   
2-36 98°C, 10 sec 56°C, 30 sec 72°C, 90sec 
36   72°C, 10 min  
 527 
 528 
21. Run 5 μL of the PCR products on a 1% agarose gel in TAE buffer (1x) to verify the 529 
presence of the amplicon  (expected size 2629 bp).  530 
 531 
22. Purify the PCR product using the Illustra DNA purification kit or equivalent reagents, 532 
and sequence the pastrel locus using the primers described in Table 2. Identify the 533 
nature of the 6 SNPs associated with viral resistance, as described previously
28
 534 
(Figure 3). If fly stocks are pastrel discordant, isogenize the genetic background using 535 
genetic crosses, or by sequential backcrosses to the control strain
27, 40
. 536 
 537 
Fly preparation: Aging flies for injection TIMING 3 days 538 
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23. Three days before injection, collect newly eclosed 0 to 2-day-old flies, and place them 539 
in a new tube. Let them age for 3 more days to reach the age range of 3-5 days on the 540 
day of injection. All control groups must be prepared in parallel. Use 3 tubes of 15-20 541 
flies for each experimental and control group. 542 
 543 
Virus preparation: Preparation of virus stock TIMING 3-6 days 544 
24. Infect S2 cells cultured to subconfluency in a T25 or T75 culture flask with the viral 545 
inoculum. If the titer of the viral isolate is known, infect cells with a low multiplicity 546 
of infection (MOI) of 0.01-0.1 to prevent the formation of defective interfering 547 
particles known to occur upon viral replication, notably with positive-sense RNA 548 
viruses
52, 53
. Use 10 mL of medium in a T25 flask, or up to 45 mL in a T75 flask.  549 
25. Monitor cell growth and morphology daily until the appearance of CPE, which is an 550 
indicator of viral replication and cell death. Harvest the cell culture supernatant, and 551 
centrifuge it for 10 min at 1,800 g. Transfer the supernatant to a new tube, and repeat 552 
the centrifugation step. Collect the supernatant and store in aliquots. 553 
PAUSE POINT:  It is recommended to prepare large amounts of virus stocks, as they 554 
can be stored for prolonged periods of time at -80°C with minimal loss of infectivity. 555 
Store in aliquots of 20-50 μL. 556 
 557 
Virus preparation: Titration by end-point dilution assay TIMING 14 days 558 
26. Seed flat-bottom 96-well plates with 100 μL of S2 cell suspension at 2.106 cells/mL.  559 
27. Fill round-bottom 96-well plates with 180 μL of sterile PBS. Make 10-fold dilution 560 
series of virus suspension, by adding 20 μL of virus stock to the first well containing 561 
180 μL of PBS, and diluting the suspension 10-fold at each step until the 12th well. 562 
28. Add 25 μL of each viral dilution to 4 replicate wells in the plate containing S2 cells.  563 
29. After 5 days, resuspend the cells and transfer 25 μL to a 96-well plate containing 100 564 
μL of fresh Schneider’s medium per well.  565 
30. After 9 more days, score CPE in each well, and calculate the viral titer using the Reed 566 
and Muench method. A ready-to-use calculation sheet has been published 
54
. 567 
 568 
Virus preparation: Dilution for injection TIMING 15 min 569 
31. Thaw an aliquot of virus stock on ice, and dilute to the appropriate concentration in 10 570 
mM Tris-HCl, pH=7.3. To prevent a decrease of viral titers and experimental 571 
variation, avoid multiple freeze/thaw cycles by preparing the virus inoculum from 572 
fresh aliquots of virus stock for each experiment.  573 
 574 
Virus Injection TIMING 1-4 hours, depending on the number of samples 575 
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32. Prepare the needle for injection as described in section Equipment Setup. 576 
CRITICAL STEP. Change the needle for each virus dilution and for the mock control 577 
(10 mM Tris-HCl, pH=7.3).  578 
33. Load the needle with the chosen inoculum. Extend the plunger of the microinjector by 579 
pressing the “empty” button until the audible signal, and then retract it 5 mm. Mount 580 
the oil-filled capillary needle on the plunger of the injector and screw it tight. View 581 
the needle through a stereomicroscope and break the tip using a thin forceps. The tip 582 
needs to be as thin as possible (≈ 0.05 mm in diameter), but should not bend upon 583 
injection. Fill the needle by dipping it in the viral suspension and pushing the “fill” 584 
button.  585 
CAUTION: the extended plunger is vulnerable. Handle with care to prevent damaging 586 
it. 587 
34. Anesthesize flies using CO2, distribute them on the pad, and inject them with 50 nL of 588 
virus inoculum. Use option A for thoracic injection or option B for abdominal 589 
injection, according to the experimenter’s preference.  590 
 591 
Option A: thoracic injection. 592 
i. Inject the thorax at the slightly lighter-coloured region between the 593 
mesopleura and pteropleura (see Fig. 5a). Make sure that the 594 
inoculum enters and stays in the body cavity, and remove the needle 595 
from the body. 596 
Option B: abdominal injection 597 
i. Inject the abdomen at the junction between the dorsal cuticle and 598 
ventral abdomen (see Fig. 5b). Make sure that the inoculum enters 599 
and stays in the body cavity, and remove the needle from the body. 600 
 601 
35. After injection, carefully transfer flies to a fresh vial. Place the vials in a horizontal 602 
position to prevent the flies from sticking to the medium while recovering from 603 
anesthesia. Once the flies have recovered, place the tube in an upright position in the 604 
incubator at the chosen temperature and analyze survival rates (steps 36-37) and viral 605 
load (steps 38-42). Both assays may be performed in parallel.  606 
?TROUBLESHOOTING 607 
 608 
Follow-up studies: measuring survival rates TIMING: 7-10 days, depending on the virus, inoculum, 609 
and sensitivity of the fly strain 610 
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36. Prepare a scoring sheet to daily report the number of dead flies. Dead flies at day 1 are 611 
excluded from the analysis, since death is most likely due to lethal injury during 612 
injection. 613 
37. Count dead flies every day, and transfer flies to a fresh vial every 3 days. Symptoms 614 
of pathology (slower movement, swollen abdomen, arrest of egg production) may be 615 
monitored using the stereomicroscope. Stop monitoring the flies, including the mock 616 
controls, when all infected flies are dead or at a pre-defined time-point. 617 
CRITICAL STEP: When close to death, flies lie at the bottom of the tube and appear 618 
immobile, but they may still be moving. Close inspection using the stereomicroscope 619 
is recommended to score flies.  620 
?TROUBLESHOOTING 621 
 622 
Follow-up studies: measuring viral load TIMING: 14 days 623 
CRITICAL: Viral load is measured similarly to titration of the virus stock (steps 26-624 
30), but requires additional sample preparation (step 38-41). 625 
38. Harvest 15 flies (from step 35) at a chosen time-point, and freeze three pools of 5 flies 626 
at -20°C. Numbers can be adapted according to the aim of the experiment.  627 
39. Homogenize the flies in 300 μL sterile PBS using a hand-operated cordless motor 628 
mounted with pestles.  629 
CRITICAL STEP: From this step onwards, the samples should be kept on ice.  630 
40. Centrifuge for 10 min at 12,000 g at 4°C and transfer the supernatant to a new tube. 631 
41. Repeat the centrifugation step, and transfer the supernatant to a new tube.  632 
PAUSE POINT. Samples can be stored for several months at -80°C for later use, or 633 
directly analyzed by end-point dilution assay.   634 
42. Proceed with the titration, as described in steps 26-30. 635 
 636 
 637 
TIMING  638 
 639 
Step 1-23: Fly preparation: Bleaching: 1 day, Tetracycline treatment: 25 days (2 generations of ≈10-12 640 
days each), SNP sequencing: 1 day, Aging: 3 days. Total preparation: 25-30 days.  641 
Step 24-31: Virus preparation: Preparation of virus stock: 3-6 days, Titration: 14 days. Total 642 
preparation: 17-20 days. 643 
Step 32-35: Virus injection: Dilution for injection: 15 min, Needle preparation: 15 min, Injection 644 
settings: 5 min, Injection: 1-4 hours. Total preparation: 2-5 hours.  645 
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Step 36-42: Follow-up studies: Survival studies: ≈ 10 days (depending on virus and inoculum), 646 
Titrations: 14 days. Total preparation: 15-24 days (depending on which time points are analyzed for 647 
titration). 648 
 649 
  650 
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TROUBLESHOOTING 651 
Troubleshooting advice is provide in Table 3. 652 
 653 
Table 3. Troubleshooting 654 
Step  Problem  Possible reason(s) Possible solution 
15 There is no offspring on 
tetracycline-containing 
medium 
Flies need more time 
to develop on 
tetracycline  medium 
 
 
Incubate vials at 25°C, make 
sure the medium is humid 
enough (if needed, add a few 
drops of water) and wait at least 
15 days to obtain progeny. 
18 The fly stock is 
Wolbachia positive 
Contamination at the 
PCR step (Step 17) 
 
Inefficient antibiotic 
treatment (step 13-14) 
Carefully repeat the PCR. 
 
 
Prepare new medium, making 
sure that the antibiotic is added 
at the right temperature. 
Prevent contamination as 
described in Box 1. 
35 Many flies died within 1 
day following injection 
Lethal injuries due to 
large needle sizes 
(step 34) 
 
 
 
 
 
 
 
Lack of experience 
 
Make sure that the capillary 
needles are thin and cause 
minimum damage to the flies. 
If needed, optimize the settings 
of the needle puller. 
 
If the tip of the needle breaks 
during an experiment, replace 
with a new needle.  
 
Repeat the experiment. 
Injection is a skill that needs 
practice. 
37 Poor food quality: 
desiccation of food and 
fungal growth. 
Few flies in the tubes 
(for example, at the 
end of a survival 
assay) 
Change tubes as often as 
necessary and carefully monitor 
food quality. 
 655 
  656 
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ANTICIPATED RESULTS 657 
 658 
Analysis of tolerance and resistance in the fly is a multi-step process that starts with the preparation of 659 
fly strains of interest. Egg bleaching and tetracycline treatment will eliminate persistent virus and 660 
Wolbachia infections, which are common in Drosophila laboratory stocks. Sequencing the pastrel 661 
locus will uncover possible discordance between fly lines in SNPs that are genetically associated with 662 
resistance to virus infection. Variables, such as gender, age, and genotypic background should remain 663 
constant, given their possible influence on experimental outcomes. Finally, well-controlled infections 664 
that include mock infections and matched genetic controls, appropriate group sizes, and replicates are 665 
essential to obtain high-quality, reproducible datasets.  666 
It was recently proposed that host defense depends on a combination of resistance and tolerance 667 
mechanisms
1, 2
. Resistance is mediated by cellular pathways that detect the pathogen and induce the 668 
expression of antiviral effectors that control its proliferation. As a consequence, it is expected that 669 
genetic inactivation of resistance mechanisms will lead to an increase in viral load, increased 670 
morbidity, and reduced survival. Typically, a fly mutant with a defect in resistance will succumb to 671 
systemic infection a few days earlier than a wild-type fly. Additionally, viral titers are expected to 672 
reach higher levels in resistance mutants, especially at the early stages of infection
10, 11, 13, 15
. This may, 673 
however, depend on the strength of the allele (i.e. whether is it a null mutant, or merely a hypomorphic 674 
allele). Moreover, it is possible that some resistance mechanisms have tissue or cell type-specific 675 
functions, and differences in viral load may only be detectable in specific tissues
15
 or for specific 676 
viruses. Alternatively, a resistance phenotype may be experimentally demonstrated by overexpression 677 
of an antiviral effector protein. It is then expected that virus replication is diminished, possibly until 678 
viral persistence or clearance, and that survival rates improve.  679 
Tolerance mechanisms limit detrimental effects of microbial infection on the host, such as direct tissue 680 
damage inflicted by the pathogen or immunopathology due to excessive immune responses.  As a 681 
consequence, fly mutants with defects in tolerance are expected to show lower survival rates upon 682 
infection, without major changes in microbial load
12
. It should be noted that specific cellular pathways 683 
may contribute to both resistance and tolerance in a pathogen-specific manner
55
. Consequently, 684 
phenotypes in survival assays may be more complex than suggested by a simple dichotomy between 685 
resistance and tolerance. 686 
Host survival rates and viral loads are relatively straightforward read-outs, which, combined with the 687 
genetic tractability of Drosophila, already have yielded and will continue to provide important insights 688 
into antiviral defense. While powerful, these assays do not capture the complex pathological 689 
consequences of infection, and could be expanded with histological assays to study tissue morphology, 690 
as well as physiological and metabolic read-outs
19, 21, 56
. More recently, models to analyze complex 691 
physiological traits, such as gut-microbiota interactions, neuroinflammation, or hormonal regulation, 692 
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have been developed in Drosophila
57
, which may also be explored in the context of resistance and 693 
tolerance to virus infection.  694 
In-depth understanding of antiviral resistance and tolerance mechanisms is important for the 695 
development of novel therapeutic approaches in humans
58
. The fruit fly and its ever-expanding 696 
experimental toolbox offers great promise for future studies.   697 
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Figure legends 841 
 842 
Figure 1. Overview of the experimental workflow. 843 
Analysis of tolerance and resistance to virus infection in Drosophila requires multiple steps. 844 
Preparation of fly stocks (left side) involves successive steps of treatment against infections with 845 
persistent viruses (egg bleaching, 1 day) and the endosymbiont Wolbachia (tetracycline treatment, 20-846 
25 days), and sequencing of the pastrel locus to evaluate if it contains SNPs that are associated with 847 
resistance to virus infection (1 day). Preparation of viral stocks (right side) requires virus stock 848 
amplification (2-5 days), titration (14 days), and preparation of the virus inoculum (15 min). Once 849 
these steps are completed, replicate pools of the flies of interest and all relevant controls are inoculated 850 
with virus (1-4 hours, depending on the size of the experiment). Flies can be injected intra-thoracically 851 
or intra-abdominally. Survival rates and viral loads are assessed over time (2-3 weeks) to characterize 852 
tolerance or resistance mechanisms.  853 
 854 
Figure 2. Practical set-up for bleaching of embryos.  855 
(a) Filters for embryo collection are built using a sectioned 50mL tube, and a nylon mesh. The center 856 
of the cap is cut out, leaving the screw thread and a small rim intact. The mesh is then immobilized 857 
between the tube and the cap. (b) After collection, embryos are incubated in 50% (v/v) household 858 
bleach for 10 min, and rinsed 3 times for 5 min in demineralized water. 859 
 860 
Figure 3. Structure of the pastrel locus and location of SNPs.  861 
Boxes represent exons (5’ and 3’-untranslated regions in gray, and coding sequence in 862 
white), horizontal lines represent introns. Chromosomal position and sequence variation are shown for 863 
each SNP. The asterisk (*) indicates the SNP with the strongest effect on viral resistance. The extent 864 
to which the other SNPs contribute to resistance could not be defined due to strong linkage 865 
disequilibrium between the SNPs
28
.  866 
 867 
Figure 4. Parameters that affect mortality in survival assays.  868 
(a) Sensitivity to DCV infection does not depend on the injection site (thoracic or abdominal). (b) 869 
Male flies are slightly more sensitive to DCV infection than female flies. (c) Sensitivity to DCV 870 
infection varies between different genetic backgrounds (w
1118
, CnBw, Oregon-R). (d) The dynamic 871 
range of survival assays is modulated by the titer of the virus inoculum. (e) Incubation temperature 872 
strongly affects survival rates after DCV infection. Data represent means and s.d. of three biological 873 
replicates of at least 15 female flies (a-e), or 15 male flies (b) per replicate for each condition. In all 874 
experiments, w
1118 
flies were inoculated by intra-thoracic injection of 1,000 TCID50 units of DCV and 875 
incubated at 25°C, unless stated otherwise (a, c, d, e). All experiments of this figure were run in 876 
parallel, the reference infection (w
1118
 female flies inoculated with 1,000 TCID50 in the thorax, and 877 
 31 
incubated at 25°C) is the same for all panels. Kaplan-Meier analyses and Cox proportional hazard 878 
analyses were used to analyze the data (Supplementary table 1). 879 
 880 
Figure 5. Intra-thoracic and intra-abdominal injection sites.  881 
Flies can be injected (a) intra-thoracically, between the pteropleura and mesopleura, or (b) intra-882 
abdominally, at the junction of the dorsal and ventral abdomen.  883 
 884 
  885 
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Box 1: Tips for preventing contamination of fly stocks 886 
 Keep fly pads and brushes clean by decontaminating weekly (or more frequently, depending 887 
on usage). Immerse the tools in a solution of 80% ethanol and 10% bleach for 30 min. Rinse 888 
thoroughly with water, followed by a rinse in 80% ethanol. Re-use when fully dried.  889 
 Keep sets of brushes and pads for infection experiments separate from those for handling non-890 
treated stocks. 891 
 Always keep the workspace clean by wiping it with a 80% ethanol/10% bleach solution before 892 
and after each use.  893 
 Keep infected and non-infected fly stocks in separate incubators, if not separate fly rooms. 894 
 Every 3 months, randomly select fly strains and verify that they are virus and Wolbachia-free 895 
by PCR assay.  896 
End of Box 1 897 
  898 
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 899 
Table 1. Viruses used in Drosophila melanogaster  900 
  901 
 902 
Virus name (abbreviation) Family  Genome  
Replication 
in S2 cells 
Cricket paralysis virus (CrPV) Dicistroviridae (+) ssRNA ✓ 
Drosophila A virus (DAV) Unassigned (+) ssRNA ✓1 
Drosophila C virus (DCV) Dicistroviridae (+) ssRNA ✓ 
Drosophila X virus (DXV) Birnaviridae dsRNA, bipartite ✓ 
Flock House virus (FHV) Nodaviridae  (+) ssRNA, bipartite ✓ 
Invertertebrate iridescent virus 6 (IIV-6) Iridoviridae  dsDNA ✓2 
Nora virus Unassigned (+) ssRNA - 
3
 
Sigma virus (DmelSV) Rhabdoviridae (-) ssRNA ✓4 
Sindbis virus (SINV) Togaviridae (+) ssRNA ✓5 
Vesicular stomatitis virus (VSV) Rhabdoviridae (-) ssRNA ✓5 
 903 
1 
DAV is able to replicate in DL2 cells, but may not reach high titers. Virus stocks may be prepared from 904 
infected flies
42
. 905 
2
 IIV-6 replicates in S2 and in DL2 cells
5, 16
, which can be used to prepare virus stocks. Alternatively, virus 906 
stocks may be prepared on Galleria mellonella, as described previously
5
. 907 
3
 Thus far, no cell line has been identified that supports high level of Nora virus replication. Virus stocks may be 908 
prepared from infected flies. 909 
4 
Sigma virus establishes persistent infections in S2 cell cultures, but is not cytopathic
59
. 910 
5
 Although SINV and VSV replicate in S2 cells, virus stocks are usually prepared on permissive mammalian cell 911 
lines, such as BHK-21 and Vero cells
8, 31
, on which these viruses reach much higher titers.  912 
  913 
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Table 2. Oligonucleotide sequences and description 914 
 915 
Target  Purpose  Primer sequence (5'-3') 
Expected 
product 
size 
DCV DCV detection 
AAAATTTCGTTTTAGCCCAGAA 
250 bp 
TTGGTTGTACGTCAAAATCTGAG 
DAV DAV detection  
AGGAGTTGGTGAGGACAGCCCA 
146 bp 
AGACCTCAGTTGGCAGTTCGCC 
Nora virus  
Nora virus 
detection 
ATGGCGCCAGTTAGTGCAGACCT 
410bp  
CCTGTTGTTCCAGTTGGGTTCGA 
Actin 42A 
Housekeeping 
gene 
GCGTCGGTCAATTCAATCTT 
522bp 
CTTCTCCATGTCGTCCCAGT 
Wolbachia 
Wolbachia 
detection
16
  
TGGTCCAATAAGTGATGAAGAAAC 
610 bp 
AAAAATTAAACGCTACTCCA 
Pastrel  
Pastrel locus 
amplification  
CCATTCCGGTTCAAAATTCTCC 
2629 bp 
CTGGGATCTGTAAGTACTGC 
Pastrel 
sequencing  
 CCATTCCGGTTCAAAATTCTCC 
n.a.  
ACATGAAGTACACCCTTACG 
TTCTGGTCGCCTTCAACTGG 
CTGGGATCTGTAAGTACTGC 
 916 
n.a., not applicable.917 
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Supplementary Data. Kaplan-Meier and Cox proportional hazard analyses  
  Kaplan-Meier  Cox 
 
Condition 
Mean survival 
time (days) 
Std. 
Error 
95% Confidence 
Interval 
Log-rank 
P value 
 Hazard ratio 
95% Confidence 
Interval 
P value 
 
Reference 
(Thorax, female, w
1118
,  
1000 TCID, 25°C) 
6.90 0.19 6.52-7.28  
   
 
      
    
 
Thorax, male, w
1118
,  
1000 TCID, 25°C 
5.67 0.21 5.26-6.07 <0.001 
 
2.10 1.32-3.34 0.002 
 
  
     
    
 
Thorax, female, Oregon-R, 
1000 TCID, 25°C 
8.44 0.49 7.47-9.40 <0.001 
 
0.58 0.36-0.93 0.023 
 
Thorax, female, CnBw,  
1000 TCID, 25°C 
7.34 0.51 6.34-8.34 0.085 
 
0.61 0.38-0.98 0.041 
 
  
     
    
 
Thorax, female, w
1118
, 
100 TCID, 25°C 
10.27 0.34 9.61-10.94 <0.001 
 
0.18 0.10-0.32 <0.001 
 
Thorax, female, w
1118
,                
10000 TCID, 25°C 
4.76 0.18 4.41-5.11 <0.001 
 
4.64 2.73-7.90 <0.001 
 
  
     
    
 
Abdomen, female, w
1118
,  
1000 TCID, 25°C 
6.34 0.20 5.95-6.73 0.104 
 
1.29 0.84-1.97 0.25 
 
  
     
    
 
Thorax, female, w
1118
,  
1000 TCID, 20°C 
9.50 0.30 8.91-10.09 <0.001 
 
0.25 0.15-0.42 <0.001 
 
Thorax, female, w
1118
,  
1000 TCID, 29°C 
3.05 0.17 2.72-3.38 <0.001 
 
19.28 9.30-39.95 <0.001 
 
Differences in survival and hazard ratios were calculated relative to the reference infection (female w
1118
 flies injected with 1000 TCID50 in the thorax, 
incubated at 25°C). Replicates were analyzed as covariates in Cox analyses.  
